Skip to main content
. 2021 Jun 8;7(7):e707. doi: 10.1097/TXD.0000000000001154

FIGURE 2.

FIGURE 2.

The 3-y cumulative graft survival rate for HIV/HCV coinfected LT recipients in the DAA era was 82% compared with 58% in the pre-DAA era (P = 0.006), while there were no statistical differences in graft survival when compared with the other control groups in the DAA era (all P > 0.05). DAA, direct-acting antiviral; HCV, hepatitis C virus; HIV, human immunodeficiency virus; LT, liver transplant.